Sun Yat-sen Memorial

Company snapshot

Sun Yat-Sen Memorial is a pharma organization headquartered in CN. Primary therapeutic focus areas include Breast Neoplasms, Radiation Injuries, Breast Cancer, Platinum-resistant Recurrent Clear Cell Ovarian Cancer, Breast Cancers. NovaPharmaNews links 7 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO sources. Pipeline phase mix: phase 3 (3), phase 2 (3).

• 7 active pipeline program(s) linked via ClinicalTrials.gov.
• 7 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Sun Yat-sen Memorial. Not investment advice.

• Peer + 0 momentum

  PUMA BIOTECHNOLOGY

  TA overlap score 38

• Peer + 0 momentum

  Eli Lilly and

  TA overlap score 32.4

• Peer + 0 momentum

  ATOSSA THERAPEUTICS

  TA overlap score 22

Recent activity

Latest pipeline, patent, and corporate events for Sun Yat-sen Memorial.

1. Jun 8, 2026 Clinical update

   Trastuzumab and neratinib — Phase 3

2. Jun 8, 2026 Clinical update

   Paclitaxel oral solution plus Subcutaneous Pertuzumab/Trastuzumab — Unknown

3. Jun 8, 2026 Clinical update

   Fulvestrant combined with Pyrotinib — Phase 3

4. Jun 8, 2026 Clinical update

   Donepezil Hydrochloride — Phase 2

5. Jun 8, 2026 Clinical update

   Carrellizumab + Capecitabine — Phase 3

View all clinical trial activity →

• What is Sun Yat-sen Memorial?

  Sun Yat-Sen Memorial is a pharma organization headquartered in CN. Primary therapeutic focus areas include Breast Neoplasms, Radiation Injuries, Breast Cancer, Platinum-resistant Recurrent Clear Cell Ovarian Cancer, Breast Cancers. NovaPharmaNews links 7 clinical program(s), 0 dr

• Is Sun Yat-sen Memorial publicly traded?

  Sun Yat-sen Memorial appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

• What drugs does Sun Yat-sen Memorial develop or market?

  We link 16 drug profile(s) where Sun Yat-sen Memorial is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/sun-yat-sen-memorial-hospital-of-sun-yat-sen-university#company-drugs.

• What are the latest developments for Sun Yat-sen Memorial?

  In the last 12 months our linked public records show 7 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Sun Yat-sen Memorial focus on?

  Sun Yat-sen Memorial focuses on Breast Neoplasms, Radiation Injuries, Breast Cancer based on our analysis of their pipeline programs and drug development activities.